




























































































382Predictors of bleeding or anemia requiring transfusion in
complex endovascular aortic repair and its impact on
outcomes in health insurance claimsChristian-Alexander Behrendt, MD,a E. Sebastian Debus, MD,a Thea Schwaneberg, MD,a Henrik C. Rieß, MD,a
Mark Dankhoff, MD,b Vladimir Makaloski, MD,a Art Sedrakyan, MD,c and Tilo Kölbel, MD,a Hamburg, Germany;
and New York, NYABSTRACT
Objective: This study aimed to determine predictors and outcomes associated with bleeding or anemia requiring
transfusion (BAT) after fenestrated or branched endovascular aneurysm repair (FB-EVAR).
Methods: Health insurance claims data of Germany’s third largest insurance provider, DAK-Gesundheit, were used to
investigate BAT in elective FB-EVAR performed between 2008 and 2017. International Classification of Diseases and
German Operations and Procedure Key codes were used.
Results: A total of 959 patients (24.8% with BAT) matching the inclusion criteria were identified during the study period.
Compared with patients without BAT, patients with BAT were older (74.4 vs 73.0 years; P ¼ .015) and suffered more
frequently from congestive heart failure (18.5% vs 9.4%), cardiac arrhythmias (26.9% vs 14.7%), and hereditary or acquired
coagulopathy (31.9% vs 6.2%; all P < .001). Coagulopathy (odds ratio [OR], 3.65; 95% confidence interval [CI], 2.29-5.84),
female sex (OR, 2.67; 95% CI, 1.78-4.00), and multiple comorbidities (OR, 1.10; 95% CI, 1.07-1.14) were independent pre-
dictors of BAT (all P < .001). BAT was associated with higher in-hospital (11.3% vs 2.6%), 30-day (12.2% vs 3.1%), and 90-day
(18.5% vs 4.4%) mortality (all P < .001). Furthermore, myocardial infarction (23.9% vs 2.8%) and paraplegia (9.7% vs 0.7%)
were more frequent in the BAT group (all P < .001). In multivariable analyses, BAT was associated with worse short-term
(OR, 3.19; 95% CI, 1.63-6.33; P ¼ .001) and long-term survival (hazard ratio, 1.62; 95% CI, 1.24-2.11; P < .001).
Conclusions: Patients with hereditary or acquired coagulopathy, patients with multiple comorbidities, and women are at
higher risk for development of BAT after FB-EVAR. The occurrence of this event was strongly associated with higher major
complication rates and worse short-term and long-term survival. This emphasizes a need to further illuminate the value
of patient blood management in FB-EVAR. (J Vasc Surg 2020;71:382-9.)
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doi.org/10.1016/j.jvs.2019.02.059dissections.2 Complex aortic repair with fenestrated or
branched stent grafts has particular challenges and
requirements and is therefore performed in compara-
tively few experienced vascular centers. Besides major
health events such as mortality and myocardial infarction
after fenestrated or branched EVAR (FB-EVAR), more out-
comes, such as major bleeding and transfusions with a
possible impact on survival, deserve further reflection.
Patient blood management (PBM) aims to identify risk
factors for and prevention strategies to avoid periopera-
tive anemia and blood transfusions to reduce costs3
and to improve outcomes in elective surgery.4 Whereas
PBM has gained significant scientific interest in other sur-
gical specialties,5,6 publications in vascular surgery and
aortic interventions are scarce and limited to standard
EVAR.7 Furthermore, the heterogeneity of definitions for
bleeding complications in available single-center studies
on FB-EVAR limits comparability and emphasizes the
need to use standardized bleeding definitions in clinical
trials.8 Hence, there is a wide sex-related variation
of bleeding complications between 0% and 42%.9-11
Rieß et al12 recently reported remarkably high transfu-
sion rates of 22% in men and nearly 39% in women
during FB-EVAR using multicenter health insurance
claims data from Germany. The aim of this study was
ARTICLE HIGHLIGHTS
d Type of Research: Multicenter retrospective non-
randomized cohort study
d Key Findings: Among 959 patients with complex
endovascular aortic repair, 25% exhibited bleeding
or anemia requiring transfusion (BAT). Female sex,
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Volume 71, Number 2to develop a reliable model for predicting bleeding or
anemia requiring transfusion (BAT) in patients undergo-
ing FB-EVAR. A secondary aim was to illuminate the
association of BAT with short-term and long-term out-
comes after FB-EVAR. We used large-scale health insur-
ance claims data of Germany’s third largest insurance
provider, DAK-Gesundheit, for this study.multiple comorbidities, and any hereditary or
acquired coagulopathy are independent predictors
of BAT. BAT was associated with significantly higher
morbidity and mortality.
d Take Home Message: The results of our study
emphasize the importance of a feasible and suitable
patient blood management for patients being
treated with complex endovascular aortic repair.METHODS
The health insurance claims data of Germany’s third
largest insurance provider, DAK-Gesundheit, include the
outpatient and in-hospital medical care provided to
approximately 6.5 million German citizens (8% of
German inhabitants). In Germany (data for 2017), approx-
imately 72 million inhabitants are insured by statutory
health insurance; another 10.5 million inhabitants are
insured by other types of insurance (eg, private health
insurance). DAK-Gesundheit data have been widely
used for health services research studies.12,13 The advan-
tages and disadvantages of this data source and its
generalizability to the German population have been
explained in another publication.14 In addition, the
health insurance funds in Germany charge the Medical
Service of the Health Funds to perform a random and
risk-based validation of data.
Inclusion criteria. All statutory health-insured patients
with at least one hospital stay between January 2008
and December 2017 for nonruptured thoracic aortic
aneurysm, TAAA, AAA, or aortic dissection by Interna-
tional Classification of Diseases, Tenth Revision (ICD-10)
codes (I71.2, I71.4, I71.6, and I71.9 for aneurysm and I71.00,
I71.01, I71.02, I71.03 for dissection) and Operations and
Procedure Key (OPS) codes for FB-EVAR of the thor-
acoabdominal or abdominal aorta (5-38a*, 8-842*) were
investigated (Fig 1).
Exclusion criteria. Ruptured aneurysms or dissections
have been excluded from this study. The German OPS
code is adapted to the International Classification of Pro-
cedures in Medicine. For the identified cases that
matched the basic search criteria, we collected data on
demographics, primary and secondary procedures
done in the hospital (OPS codes), coded comorbidities
(ICD-10 codes), and discharge destination. For the long-
term survival analyses, we censored patients whose
insurance contract expired within the follow-up period.
The data set for this study was stratified into relevant
subgroups (whether BAT was coded or not). The first
repair procedure was included as the primary case (no
reintervention cases during the study period were
included).
Health insurance claims data consist of standardized
information used for reimbursement or administration
of medical care performed by health care providers
using the ICD-9 or ICD-10 codes for comorbidities. In1998, Elixhauser et al15,16 introduced a systematic classifi-
cation to identify relevant comorbidities among primary
or secondary diagnoses at the time of discharge. Major
comorbidities, such as congestive heart failure, cardiac
arrhythmias, chronic pulmonary disease, diabetes, and
chronic renal failure, were categorized in 30 commonly
accepted groups. van Walraven et al17 used the Elix-
hauser classification and developed a linear sum score
ranging from 7 points (for drug abuse) to þ12 points
(for metastatic cancer) to adjust multivariable models
that estimate odds for in-hospital survival using a single
metric covariate.
Coagulopathy (also commonly known as bleeding dis-
order) was stated if any hereditary (eg, von Willebrand
disease) or acquired (eg, vitamin K deficiency or intake
of anticoagulants) condition is affecting the blood’s abil-
ity to coagulate.
BAT was stated if any bleeding complication or
bleeding anemia (ICD-10 codes D62, T79.2, R57.1, and
R58) was coded together with a blood transfusion (OPS
8-800*).
Statistical analysis. Statistical analyses and data report-
ing are in accordance with the statistical and data
reporting guidelines of the European Journal of Cardio-
thoracic Surgery and Interactive Cardiovascular and
Thoracic Surgery.18 Tests of normality were conducted
using the Kolmogorov-Smirnov test. The tests for cate-
gorical variables were c2 test and two-way t-test for
continuous variables. For non-normally distributed data,
a Kruskal-Wallis test was performed. Relative risks
including 95% confidence intervals (CIs) were addition-
ally calculated for categorical outcomes. Bivariate ana-
lyses were conducted to investigate the association of
BAT with in-hospital and long-time survival. A predictive
model was developed for the entire cohort including
covariates from bivariate differences (Table I). Multivari-
able regression models were used to determine the
independent association of BAT with in-hospital and
Fig 1. Flow chart: 959 patients with fenestrated or branched endovascular aneurysm repair (FB-EVAR) were
identified during the study period (2008-2017).
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approach. The models included older age, female sex,
and higher van Walraven comorbidity score. Kaplan-
Meier survival curves were used to determine long-term
survival and a log-rank test was used. Patients with
unknown mortality were censored. Sensitivity analyses
using the landmark approach were used to calculate
survival, conditional on surviving the procedure (30 days).
Statistical significance was defined as P value <.05. No
adjustment for multiple testing was performed. All sta-
tistical analyses were performed with software R version
3.3.2 (The R Foundation for Statistical Computing, Vienna,
Austria).
Ethical considerations. This study complies with the
Declaration of Helsinki. For a retrospective analysis of
anonymized health insurance claims data, no local ethic
committee approval was required, and no patient
informed consent was obtained for the study.RESULTS
A total of 959 patients (796 [83%] male and 163 [17%]
female) underwent FB-EVAR between January 2008
and December 2017 (Fig 1). Preoperative anemia was
documented in six (0.6%) of the patients. BAT occurred
in 238 (24.8%) patients. All BAT occurred during theoperation (100%) and during the following hospital stay
(90.3%). Of those 238 patients, 63 (26.5%) were female
and 175 (73.5%) were male. Baseline characteristics and
coexisting conditions are shown in Table I. Patients’
mean age (74.4 vs 73.0 years; P < .001) and mean van
Walraven comorbidity score (11.3 vs 5.3; P < .001) were
significantly higher in the BAT group. Among patients
in the BAT group, a higher proportion of congestive heart
failure, cardiac arrhythmia, coagulopathy, and renal and
liver diseases was present compared with patients
without BAT (Table I).
Perioperative outcomes of the study patients are shown
in Table II. A total of 51 (5.3%) deaths occurred after
30 days, 76 (7.9%) deaths occurred after 90 days, and a
total of 267 (27.8%) deaths occurred among the entire
cohort during the study period (result not shown in
table). Higher in-hospital mortality (11.3% vs 2.6%;
P < .001), 30-day mortality (12.2% vs 3.1%; P < .001), and
90-day mortality (18.5% vs 4.4%; P < .001) were shown
in the BAT group compared with patients without BAT.
Furthermore, the rate of major perioperative morbidity,
such as acute respiratory and renal failure, acute myocar-
dial infarction, stroke or transient ischemic attack, and
colonic and peripheral ischemia, was significantly higher
in the BAT group compared with the non-BAT group. A
higher rate of paraplegia was found in the BAT group
Table I. Baseline characteristics and Elixhauser coding groups of the study patients
FB-EVAR
BAT: Yes BAT: No P value
No. of patients 238 721
Age, years, mean (SD) 74.44 (7.49) 73.00 (7.94) .015
Female sex 63 (26.5) 100 (13.9) <.001
van Walraven comorbidity score, mean (SD) 11.34 (7.49) 5.29 (6.00) <.001
Congestive heart failure 44 (18.5) 68 (9.4) <.001
Cardiac arrhythmias 64 (26.9) 106 (14.7) <.001
Valvular disease 19 (8.0) 42 (5.8) .303
Pulmonary circulation disorders 5 (2.1) 4 (0.6) .079
Peripheral vascular disorders 229 (96.2) 533 (73.9) <.001
Hypertension 170 (71.4) 423 (58.7) .001
Chronic pulmonary disease 43 (18.1) 89 (12.3) .035
Diabetes, uncomplicated 31 (13.0) 70 (9.7) .186
Diabetes, complicated 11 (4.6) 24 (3.3) .470
Renal failure (all stages) 96 (40.3) 161 (22.3) <.001
Liver disease 10 (4.2) 4 (0.6) <.001
Peptic ulcer disease excluding bleeding 1 (0.4) 0 (0.0) .560
Lymphoma 3 (1.3) 3 (0.4) .338
Metastatic cancer 0 (0.0) 2 (0.3) 1.000
Solid tumor without metastasis 6 (2.5) 19 (2.6) 1.000
Rheumatoid arthritis or collagen vascular disease 2 (0.8) 7 (1.0) 1.000
Coagulopathy 76 (31.9) 45 (6.2) <.001
Obesity 24 (10.1) 71 (9.8) 1.000
Weight loss 7 (2.9) 2 (0.3) .001
Fluid and electrolyte disorders 98 (41.2) 109 (15.1) <.001
Blood loss anemia 1 (0.4) 1 (0.1) .995
Deficiency anemia 1 (0.4) 3 (0.4) 1.000
Alcohol abuse 1 (0.4) 1 (0.1) .995
Drug abuse 8 (3.4) 5 (0.7) .006
BAT, Bleeding and anemia requiring transfusion; FB-EVAR, fenestrated or branched endovascular aneurysm repair; SD, standard deviation.
Values are reported in total numbers (%) unless otherwise indicated. Significant P values are marked in bold.
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patients, a longer hospital stay and higher rates of trans-
fer to other hospitals or nursing homes were found in the
BAT group. In long-term follow-up, BAT patients required
significantly more aneurysm-related reoperations
compared with their non-BAT counterparts (90.8% vs
69.9%; P < .001; Table II).
Predictors of the occurrence of BAT. Independent pre-
dictors of BAT after FB-EVAR in the entire cohort are
listed in Table III. In adjusted analysis, female sex (odds
ratio [OR], 2.672; 95% CI, 1.780-3.999; P < .001), higher van
Walraven comorbidity score (OR, 1.104; 95% CI, 1.071-1.139;
P < .001), and hereditary or acquired coagulopathy (OR,
3.647; 95% CI, 2.288-5.844; P < .001) were associated with
higher odds of BAT. Older age (increase by 1 year) of
the patients and renal failure did not add significantly to
the model.Association of BAT with in-hospital mortality (regres-
sion models for entire cohort). Results of the multivari-
able logistic regression for in-hospital mortality are
shown in Table IV. Older age (increase by 1 year) of the
patients (OR, 1.056; 95% CI, 1.012-1.104; P ¼ .015), female
sex (OR, 2.613; 95% CI, 1.335-4.976; P ¼ .004), and BAT (OR,
3.194; 95% CI, 1.633-6.325; P ¼ .001) were associated with
higher odds of in-hospital mortality. No significant
impact was found for a higher van Walraven comorbidity
score.
Association of BAT with long-term survival (regression
models for entire cohort). Ten patients were censored
because of the expiration of their health insurance con-
tract, and the mean follow-up duration was 2.6 years.
Kaplan-Meier survival curves are shown in Fig 2 (entire
cohort). Results of adjusted analysis using the Cox pro-
portional hazards model for the entire cohort are shown
Table III. Independent predictors for the occurrence of
bleeding or anemia requiring transfusion (BAT)
FB-EVAR
OR 95% CI P value
Older age of the patient
(increase by 1 year)
1.008 0.987-1.030 .460
Female sex (vs male) 2.672 1.780-3.999 <.001
van Walraven comorbidity
score (increase by 1 point)
1.104 1.071-1.139 <.001
Coagulopathy 3.647 2.288-5.844 <.001
Renal failure 1.129 0.741-1.712 .570
CI, Confidence interval; FB-EVAR, fenestrated or branched endovas-
cular aneurysm repair; OR, odds ratio.
Significant P values are marked in bold.
Table II. Perioperative outcomes after fenestrated or branched endovascular aneurysm repair (FB-EVAR)
BAT: Yes BAT: No P value Relative risk (95% CI)
No. of patients 238 721
In-hospital mortality 27 (11.3) 19 (2.6) <.001 4.30 (2.44-7.60)
30-Day mortality 29 (12.2) 22 (3.1) <.001 3.99 (2.34-6.81)
90-Day mortality 44 (18.5) 32 (4.4) <.001 4.17 (2.71-6.41)
Acute respiratory insufficiency 66 (27.7) 30 (4.2) <.001 6.66 (4.44-10.00)
Acute renal failure 57 (23.9) 20 (2.8) <.001 8.63 (5.30-14.06)
Acute myocardial infarction 16 (6.7) 7 (1.0) <.001 6.92 (2.88-16.63)
Stroke or TIA 7 (2.9) 4 (0.6) .008 5.30 (1.57-17.95)
Paraplegia 23 (9.7) 5 (0.7) <.001 13.94 (5.36-36.25)
Pneumonia 26 (10.9) 10 (1.4) <.001 7.88 (3.86-16.09)
Colonic ischemia 13 (5.5) 3 (0.4) <.001 13.33 (3.77-45.67)
Acute limb ischemia 23 (9.7) 15 (2.1) <.001 4.65 (2.46-8.75)
Lower extremity amputation 3 (1.3) 0 (0.0) .019 e
Sepsis or SIRS 16 (6.7) 1 (0.1) <.001 48.47 (6.46-363.55)
Gastric ulcer 6 (2.5) 5 (0.7) .052 3.64 (1.12-11.80)
Transfer to another hospital 26 (10.9) 9 (1.2) <.001 8.75 (4.16-18.41)
Discharged to rehabilitation or nursing facility 23 (9.7) 7 (1.0) <.001 9.95 (4.33-22.90)
Length of total hospital stay, days, median (IQR) 16.00 (10.00-27.00) 9.00 (7.00, 14.00) <.001 e
Postoperative hospital stay, days, median (IQR) 13.00 (7.00-22.00) 7.00 (5.00, 10.00) <.001 e
Aneurysm-related hospital readmissions 238 (100.0) 721 (100.0) 1.000 e
Aneurysm-related reoperations 216 (90.8) 504 (69.9) <.001 1.30 (1.22-1.38)
BAT, Bleeding and anemia requiring transfusion; CI, confidence interval; IQR, interquartile range; SIRS, systemic inflammatory response syndrome; TIA,
transient ischemic attack.
Values are reported in total numbers (%) unless otherwise indicated. Significant P values are marked in bold.
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(hazard ratio [HR], 1.045; 95% CI, 1.028-1.062; P < .001),
higher van Walraven comorbidity score (HR, 1.039; 95%
CI, 1.022-1.056; P < .001), and BAT (HR, 1.615; 95% CI, 1.240-
2.104; P < .001) were associated with shorter long-term
survival. No significant impact of female sex was found.
Additional analyses of survival conditional on surviving
the procedure. Sensitivity analyses estimated the associ-
ation of BAT with survival beyond discharge (patients
who survived at least the first 30 days after the procedure;Fig 3). Older age of the patients (HR, 1.048; 95% CI, 1.029-
1.067; P < .001), higher van Walraven comorbidity score
(HR, 1.036; 95% CI, 1.017-1.055; P< .001), and BAT (HR, 1.403;
95% CI, 1.037-1.898; P ¼ .028) added significantly to
the model, whereas female sex showed no significant
impact on long-term survival (HR, 1.237; 95% CI, 0.874-
1.750; P ¼ .231; results not shown in the table).
DISCUSSION
BATduring complex aortic repair is a frequent complica-
tion in 25% of patients. Female sex, higher van Walraven
comorbidity score, and any hereditary or acquired coagul-
opathy are independent predictors of this complication.
BAT was associated with significantly higher morbidity
and mortality, emphasizing the importance of a valid
PBM in complex endovascular aortic repair.
Few studies on elective major vascular surgery report
similarly high postoperative transfusion rates.8,19 Evidence
is strong that bleeding or transfusion is associated with
worse outcomes after percutaneous coronary interven-
tion,20 cardiac surgery,21,22 and major vascular surgery.8,19
In a large multicenter quality improvement registry
covering some 3000 patients from 22 hospitals in the
United States, Obi et al7 revealed an increased 30-day
morbidity and mortality in patients with transfusions
after open peripheral artery disease procedures or any
Table IV. Logistic regression results for in-hospital mor-
tality for fenestrated or branched endovascular aneurysm
repair (FB-EVAR) by different risk factors
FB-EVAR
OR 95% CI P value
Older age of the patient
(increase by 1 year)
1.056 1.012-1.104 .015
Female sex (vs male) 2.613 1.335-4.976 .004
van Walraven comorbidity
score (increase by 1 point)
1.034 0.992-1.077 .105
Occurrence of BAT 3.194 1.633-6.325 .001
BAT, Bleeding or anemia requiring transfusion; CI, confidence interval;
OR, odds ratio.
Significant P values are marked in bold.
Table V. Cox regression (entire cohort) results for long-
term mortality for fenestrated or branched endovascular
aneurysm repair (FB-EVAR) by different risk factors
FB-EVAR
HR 95% CI P value
Older age of the patient
(increase by 1 year)
1.05 1.03-1.06 <.001
Female sex (vs male) 1.37 1.01-1.84 .041
van Walraven comorbidity
score (increase by 1 point)
1.04 1.02-1.06 <.001
Occurrence of BAT 1.62 1.24-2.11 <.001
BAT, Bleeding or anemia requiring transfusion; CI, confidence interval;
HR, hazard ratio.
Significant P values are marked in bold.
Fig 2. Kaplan-Meier survival analysis for the entire cohort.
The light green and light red areas mark the standard
deviation. P value was calculated using the log-rank test.
BAT, Bleeding or anemia requiring transfusion.
Fig 3. Kaplan-Meier survival analysis conditional on sur-
viving the first 30 days (landmark analysis). The light green
and light red areas mark the standard deviation. P value
was calculated using the log-rank test. BAT, Bleeding or
anemia requiring transfusion.
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authors found female sex to be independently associ-
ated with the occurrence of transfusions and underlined
the need for prospective transfusion threshold studies in
vascular surgery patients. In accordance with the find-
ings by Rieß et al,12 this study could confirm a strong
independent predictive value of female sex on the
likelihood that BAT will occur. This sex difference is
not completely new. In a large multicenter study
enrolling 6530 patients with elective cardiac surgery,
hip replacement surgery, and knee replacement surgery,
Gombotz et al23 found higher transfusion rates and vol-
ume in women compared with men. The authors
concluded that clinicians tend to apply the same abso-
lute transfusion thresholds for both sexes, leading toovertransfusion in female patients. Our data including
FB-EVAR add to the knowledge base and confirm the as-
sociation between transfusion rates and worse
outcomes.
Smaller iliac access vessels in female patients may
account for a higher frequency of substantial blood loss
during FB-EVAR. Bilateral large-bore access is required
for the fenestrated main bodies and for a contralateral
20F to 24F large sheath to carry the sheaths for the target
vessels. Another limitation of FB-EVAR in female patients
due to smaller access vessels appears to be rotational
control.24
Besides remarkably higher rates of respiratory, renal,
and cardiac events in the BAT group, the difference of
388 Behrendt et al Journal of Vascular Surgery
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cial attention. Blood transfusion requirement is a known
risk factor for spinal cord ischemia (SCI) in open repair of
TAAA.25 Available studies on SCI after endovascular
repair for TAAA rarely report blood loss and transfusion.26
Although intraoperative blood loss with a transfusion
requirement appears to be an important factor for major
adverse outcomes like SCI, no recommendations on
transfusion threshold and PBM can be found in current
guidelines for TAAA repair.27 However, for elective surgery
with high risk of subsequent transfusions, a blood hemo-
globin threshold of 11 g/dL in men and 10 g/dL in women
is commonly accepted in Germany to initiate further dif-
ferential diagnostics before the procedure.28 One of the
limitations to reporting of blood loss in endovascular pro-
cedures is the difficulty in estimating blood loss from
endovascular sheaths into the patient’s draping. In this
study, the occurrence of bleeding or blood transfusion
was strongly associated with higher rates of paraplegia,
confirming prior results.
Colonic ischemia, another devastating complication,
was also associated with the occurrence of BAT after
FB-EVAR in our study. After elective endovascular AAA
repair, the incidence of colonic ischemia was reported
to be approximately 0.5% to 1.0%, with increased odds
of morbidity and mortality.29-31 Interestingly, to the best
of our knowledge, no valid association between
bleeding, transfusion, and colonic ischemia after com-
plex aortic repair was reported before this study.
The results of our study emphasize the importance
of PBM for patients being treated with FB-EVAR. High-
volume centers worldwide already use cell savers to
minimize intraoperative blood loss, but to the best of
our knowledge, there is no broad awareness and no
evidence-based approach to implement a sex-related
PBM in complex endovascular aortic repair. We suggest
using a commonly consented reporting standard for
bleeding and transfusion as stated by the Bleeding
Academic Research Consortium.8 According to
Clevenger et al,4 PBM in elective FB-EVAR should focus
on three pillars of care: the detection and treatment of
preoperative anemia, reduction of perioperative blood
loss, and harnessing and optimizing the patient-specific
physiologic reserve of anemia.32 Existing thresholds vary
significantly throughout the world. To evaluate the
benefit and potential harms of PBM and sex-related
thresholds in elective complex aortic repair, a prospec-
tive randomized and controlled trial should be
conducted.
This study has limitations. First, no anatomic, device-
specific, or laboratory information, such as access or iliac
vessel diameter or preoperative hemoglobin level, was
available to adjust for these possible confounders. The
complexity and duration of the procedure probably
have an impact on outcomes. Hence, the question arises
as to whether women are more frequently anemic atpresentation and are therefore predisposed to more
transfusions. It also remains uncertain how an inhomo-
geneous transfusion threshold in real-world practice
might confound treatment practice. However, the results
of this study are interesting and hypothesis generating.
Future prospective studies are needed to examine
possible confounders. Second, it has to be highlighted
that nonrandomized retrospective studies are limited
to associations. It is for the vascular community to
ponder statistical significance vs clinical relevance. Third
and last, the primary purpose of the data collection
should be taken into account in using it for secondary
purposes. All data used for research purposes should
undergo validation. Against that backdrop, health insur-
ance funds perform random cross-checks with patient
files on a regular basis.33,34 Certainly, coding errors are
possible, but they would affect both study groups
equally.35
CONCLUSIONS
Patients with coagulopathy, patients with multiple
comorbidities, and women are at higher risk for develop-
ment of BAT after FB-EVAR. The occurrence of this event
was strongly associated with higher major complication
rates and worse short-term and long-term survival. This
emphasizes a need to further illuminate the value of
PBM in FB-EVAR.
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